4.6 Review

The epigenetic/noncoding origin of tumor dormancy

Journal

TRENDS IN MOLECULAR MEDICINE
Volume 21, Issue 4, Pages 206-211

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2015.02.005

Keywords

dormancy; dormancy-competent cancer stem cells; epigenetic/noncoding interactome; metastasis; therapy resistance

Funding

  1. Canadian Institutes of Health Research
  2. Urology Foundation
  3. BC Cancer Foundation
  4. Movember Foundation
  5. Prostate Cancer Canada-Movember Foundation Team Grant [T2013-1]
  6. Terry Fox New Frontiers Program on Prostate Cancer Progression
  7. Michael Smith Foundation for Health Research [5629]
  8. Prostate Cancer Foundation-BC Awards

Ask authors/readers for more resources

Cancer stem cells (CSCs) have been implicated as the seeds of treatment resistance and metastasis, which are the most deadly features of a neoplasm. However, an unequivocal definition of the CSC phenotype is still missing. A common feature of normal and aberrant stem cells is their ability to enter a prolonged dormant state. Cancer dormancy is a key mechanism for treatment resistance and metastasis. Here we propose a unified definition of dormancy-competent CSCs (DCCs) as the neoplastic subpopulation that can plastically alternate periods of dormancy and rapid growth. Irreversible DNA mutations can hardly account for this versatile behavior, and based on emerging evidence we propose that cancer dormancy is a nongenetic disease driven by the flexible nature of the epigenetic/noncoding interactome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available